正在进行生物治疗的患者RA活性和持续缓解的评估

Q3 Medicine
T. Shivacheva
{"title":"正在进行生物治疗的患者RA活性和持续缓解的评估","authors":"T. Shivacheva","doi":"10.35465/27.1.2019.PP16-23","DOIUrl":null,"url":null,"abstract":"The aim of the study is to establish the frequency and sustained remission and low disease activity in patients with RA in the course of long-term treatment with synthetic and biological means (DMARDs) in real conditions. In the conditions of retrospective data analysis of real clinical practice, there were included 209 patients suffering from RA. Activity indexes of RA in all patients were analyzed in the last year of treatment with bDMARDs. The average age of the patients is 59,01 years old. The dominants sex is female (84.6%). The beginning of treatment with biological therapy is delayed with the average of 8.21 year. In all activity indexes of RA, which were monitored in the beginning of the 6th and the 12th months, there was established a significant difference in their variation for the periods surveyed. There is a general trend towards lowering the values of our indicators. In the beginning of the monitored period, the patients going into remission (DAS28 CRP) are approximately 3 times less – 11% (n = 23) in comparison with those in the end of the study – 32.99% (n = 64) (p < 0.001). In 10% of the cases a sustained remission is observed by both combined indexes (DAS28 ESR and DAS28 CRP) (p < 0.001). Today the accurate way is the “treat to target” strategy. The purpose is lowering the activity of the disease to very low levels (or remission) and achieving a long-term remission which is now real and achievable.","PeriodicalId":38954,"journal":{"name":"Revmatologiia (Bulgaria)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Evaluation of the activity of RA and sustained remission in patients ongoing biological therapy\",\"authors\":\"T. Shivacheva\",\"doi\":\"10.35465/27.1.2019.PP16-23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The aim of the study is to establish the frequency and sustained remission and low disease activity in patients with RA in the course of long-term treatment with synthetic and biological means (DMARDs) in real conditions. In the conditions of retrospective data analysis of real clinical practice, there were included 209 patients suffering from RA. Activity indexes of RA in all patients were analyzed in the last year of treatment with bDMARDs. The average age of the patients is 59,01 years old. The dominants sex is female (84.6%). The beginning of treatment with biological therapy is delayed with the average of 8.21 year. In all activity indexes of RA, which were monitored in the beginning of the 6th and the 12th months, there was established a significant difference in their variation for the periods surveyed. There is a general trend towards lowering the values of our indicators. In the beginning of the monitored period, the patients going into remission (DAS28 CRP) are approximately 3 times less – 11% (n = 23) in comparison with those in the end of the study – 32.99% (n = 64) (p < 0.001). In 10% of the cases a sustained remission is observed by both combined indexes (DAS28 ESR and DAS28 CRP) (p < 0.001). Today the accurate way is the “treat to target” strategy. The purpose is lowering the activity of the disease to very low levels (or remission) and achieving a long-term remission which is now real and achievable.\",\"PeriodicalId\":38954,\"journal\":{\"name\":\"Revmatologiia (Bulgaria)\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-04-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revmatologiia (Bulgaria)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35465/27.1.2019.PP16-23\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revmatologiia (Bulgaria)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35465/27.1.2019.PP16-23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

摘要

本研究的目的是确定RA患者在实际条件下使用合成和生物方法(DMARD)进行长期治疗的频率、持续缓解和低疾病活动性。在实际临床实践的回顾性数据分析条件下,纳入209例RA患者。分析所有患者在bDMARD治疗的最后一年中RA的活性指标。患者的平均年龄为59,01岁。主要性别为女性(84.6%),生物治疗开始时间延迟,平均8.21年。在第6个月和第12个月初监测的RA的所有活动指数中,它们在调查期间的变化存在显著差异。总体趋势是降低我们各项指标的价值。在监测期开始时,病情缓解的患者(DAS28 CRP)大约减少了3倍,比研究结束时减少了11%(n=23),减少了32.99%(n=64)(p<0.001)。在10%的病例中,通过两个综合指标(DAS28ESR和DAS28CRP)观察到持续缓解(p<001)。如今,准确的方法是“靶向治疗”策略。其目的是将疾病的活性降低到非常低的水平(或缓解),并实现长期缓解,这是现在真实和可实现的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evaluation of the activity of RA and sustained remission in patients ongoing biological therapy
The aim of the study is to establish the frequency and sustained remission and low disease activity in patients with RA in the course of long-term treatment with synthetic and biological means (DMARDs) in real conditions. In the conditions of retrospective data analysis of real clinical practice, there were included 209 patients suffering from RA. Activity indexes of RA in all patients were analyzed in the last year of treatment with bDMARDs. The average age of the patients is 59,01 years old. The dominants sex is female (84.6%). The beginning of treatment with biological therapy is delayed with the average of 8.21 year. In all activity indexes of RA, which were monitored in the beginning of the 6th and the 12th months, there was established a significant difference in their variation for the periods surveyed. There is a general trend towards lowering the values of our indicators. In the beginning of the monitored period, the patients going into remission (DAS28 CRP) are approximately 3 times less – 11% (n = 23) in comparison with those in the end of the study – 32.99% (n = 64) (p < 0.001). In 10% of the cases a sustained remission is observed by both combined indexes (DAS28 ESR and DAS28 CRP) (p < 0.001). Today the accurate way is the “treat to target” strategy. The purpose is lowering the activity of the disease to very low levels (or remission) and achieving a long-term remission which is now real and achievable.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Revmatologiia (Bulgaria)
Revmatologiia (Bulgaria) Medicine-Rheumatology
CiteScore
0.30
自引率
0.00%
发文量
21
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信